Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29909581
Publication Date : //

Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.


Switch maintenance therapy, using alternative agents that were not administered during induction chemotherapy, is a treatment option for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab is known to increase the efficacy of other chemotherapeutic agents; however, switch maintenance therapy with docetaxel and bevacizumab has not been adequately studied. The goal of this study was to evaluate the efficacy and safety of switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin, pemetrexed, and bevacizumab. Chemotherapy-naïve non-squamous NSCLC patients received induction therapy of four cycles of cisplatin (75 mg/m), pemetrexed (500 mg/m), and bevacizumab (15 mg/kg). Patients who achieved disease control after induction therapy then received maintenance therapy with docetaxel (50 mg/m) and bevacizumab (15 mg/kg) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival from enrollment. This study enrolled 49 NSCLC patients, among which 38 (77.6%) completed the four cycles of induction therapy and received maintenance therapy. The median progression-free survival from enrollment was 7.8 months (95% confidence interval: 4.7-11.0 months). The most common toxicities of grade 3 or higher were neutropenia (68.4%), leukopenia (50.0%), febrile neutropenia (31.8%), and hypertension. Switch maintenance therapy with docetaxel and bevacizumab following induction therapy with cisplatin, pemetrexed, and bevacizumab demonstrated modest efficacy and frequent hematologic toxicity in non-squamous NSCLC patients.

Authors : Nishimoto Koji , Karayama Masato , Inui Naoki , Yasui Hideki , Hozumi Hironao , Suzuki Yuzo , Furuhashi Kazuki , Fujisawa Tomoyuki , Enomoto Noriyuki , Nakamura Yutaro , Inami Nao , Matsuura Shun , Kaida Yusuke , Matsui Takashi , Asada Kazuhiro , Matsuda Hiroyuki , Fujii Masato , Toyoshima Mikio , Imokawa Shiro , Suda Takafumi ,

Related products :

Catalog number Product name Quantity
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
HTPB-1511 Human Lung Tumor Blot II - Matching Pair #1 (A549, small, non-small, squamous cell carcinoma, matched normal lung tissue) 1
LUC1504 Lung cancer tissue array (small cell lung cancer), 75 cases, 150 samples (1.1mm), set 4 75 Cases
HTPB-1511 Human Lung Tumor Blot II - Matching Pair _1 (A549, small, non-small, squamous cell carcinoma, matched normal lung tissue) Species Reactivity: Human 1 Product tipe: Pre-made WB
HTPB-1510 Human Lung Tumor Blot I - All Malignant (small, non-small cell differentiated adenocarcinoma, squamous pleomorphic) 1
HTPB-1511 Human Lung Tumor Blot II _ Matching Pair 1 (A549, small, non_small, squamous cell carcinoma, matched normal lung tissue) 1
B437 Brain Heart Infusion w_PABA USE For examination of blood from patients under sulphonamide therapy. Qty per Litre of Medium: 37
B437 Brain Heart Infusion w_PABA USE : For examination of blood from patients under sulphonamide therapy. 5x500gm
UB-E05305 Avastin per Bevacizumab ELISA Kit 96T
orb61244 Erlotinib Erlotinib hydrochloride is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. For research use only. 100 mg
HTPB-1510 Human Lung Tumor Blot I - All Malignant (small, non-small cell differentiated adenocarcinoma, squamous pleomorphic) Species Reactivity: Human 1 Product tipe: Pre-made WB
AP-303-B Bevacizumab-treated Tumors, Peptide Aptamer, Biotinylated 1 mg
AP-303-U Bevacizumab-treated Tumors, Peptide Aptamer, Unlabelled 5 mg
A1045-100 Anti-VEGF (Bevacizumab), humanized Antibody 50
200-800-AVG Avastin Bevacizumab (Anti-VEGF) ELISA Kit for human, 96 tests 1 kit
AP-303-F Bevacizumab-treated Tumors, Peptide Aptamer, FITC labelled 1 mg
AP-303-U Bevacizumab-treated Tumors, Peptide Aptamer, Unlabelled Species Reactivity: 5 mg Product tipe: Peptide Aptamers
AP-303-B Bevacizumab-treated Tumors, Peptide Aptamer, Biotinylated Species Reactivity: 1 mg Product tipe: Peptide Aptamers
200-870-ID24 Avastin Bevacizumab identification Counterfeit detection ELISA Kit, 24 tests 1 kit
'CC04-01-001 Human Lung carcinoma tissue array (Large small cell adenocarcinoma squamous) tissues 7 x 9
AP-303-F Bevacizumab-treated Tumors, Peptide Aptamer, FITC labelled Species Reactivity: 1 mg Product tipe: Peptide Aptamers
HCA184P HUMAN ANTI BEVACIZUMAB:HRP Monoclonal Antibody Host: HuCAL IgG1 0.1 mg
HCA185 HUMAN ANTI BEVACIZUMAB Monoclonal Antibody Host: HuCAL IgG1 0.1 mg
HCA184 HUMAN ANTI BEVACIZUMAB Monoclonal Antibody Host: HuCAL IgG1 0.1 mg
orb60678 Verteporfin Verteporfin(Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy. For research use only. 10 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur